secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001213900-25-102222
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M
--------------------------------------------------------------------------------

- Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.
- Omnibus equity plan share reserve raised from 470,000 to 1,400,000 shares, plus automatic annual increase.
- All four director nominees re-elected; ratification of Salberg & Company as auditor approved.
- Reverse split proposal received 3,896,499 for vs 1,253,332 against; plan amendment got 1,343,678 for vs 514,675 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025102222/0001213900-25-102222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025102222/ea0262461-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-102222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer